-+ 0.00%
-+ 0.00%
-+ 0.00%

PHARMING ANNOUNCES POSITIVE PHASE II TOPLINE DATA FOR LENIOLISIB IN PIDS WITH IMMUNE DYSREGULATION ACCEPTED AS LATE-BREAKING ABSTRACT AT ESID 2026

Reuters·09/22/2026 05:00:02

Please log in to view news